Biotech IV Monitor

KYKOF — Kyowa Kirin Co. Ltd.

$7.6B market cap · 5 upcoming readouts tracked

Clinical trial readout dates for Kyowa Kirin Co. Ltd., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is March 2027.

Next readoutMarch 2027in ~4 months
Upcoming readouts51 Phase 3
Market cap$7.6B

Recently completed

The registry reports these trials have finished collecting primary data. Results often follow within months, and the company may already have reported.

Phase 2 KHK4951
Neovascular Age-Related Macular Degeneration (nAMD) · NCT06116890
June 2026
Primary data collected

Upcoming readouts

Phase 2 ziftomenib
Acute Myeloid Leukemia (AML) · NCT07623616
March 2027
Recruiting
Phase 1/2 KK2430
Hematologic Neoplasms · NCT07629726
April 2027
Recruiting
Phase 2 ME-401
Indolent B-cell Non-Hodgkin's Lymphoma · NCT04533581
May 2028
Ongoing
Phase 3 KK8398
Achondroplasia · NCT06926491
May 2029
Ongoing
Phase 1/2 KK8123
X-linked Hypophosphatemia · NCT06525636
June 2030
Recruiting

Companies working on similar indications

Discussion

No messages yet. If you follow KYKOF, you can start the conversation.
Track KYKOF in real time
See live implied volatility for KYKOF and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on KYKOF
Contact — questions or corrections about KYKOF: dukeupt@gmail.com